… benefit from erlotinib. To clarify the role of EGFR in the outcome of non–small-cell lung cancer,
we … of EGFR, and mutation status of the gene in a subgroup of patients in the BR.21 study. …

… to determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs
survival in non–small-cell lung cancer after the failure of first-line or second-line chemotherapy. …

… Although treatment with cytotoxic agents has produced modest survival improvement in
patients with stage III and IV non-small cell lung cancer (NSCLC), it appears that a plateau has …

… Symptom improvement in lung cancer patients treated with erlotinib: quality of life
analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. …

… We investigated whether erlotinib improves clinical outcome in these patients. … patients to
receive erlotinib and 320 to receive placebo. We followed up patients until March 31, 2011. 657 …

… erlotinib for non-small cell lung cancer (NSCLC), we performed a population-based observational
study. The study involved 307 patients treated with erlotinib … The tumor response and …

… phase II trial, the efficacy and safety of gefitinib and erlotinib was evaluated as the second-line
therapy for advanced non-small cell lung cancer (NSCLC). Patients and methods …

… on 4068 concentration samples from 1047 patients receiving erlotinib as a single agent or in
… erlotinib exposure in non-small cell lung cancer patients treated with single-agent erlotinib. …

… This phase II study of erlotinib in patients with HER1/EGFR-expressing non–small-cell lung
cancer previously treated with platinum-based chemotherapy evaluated tumor response, …

… Erlotinib (Tarceva) is a reversible and highly specific inhibitor … of 57 patients with EGFR-positive
non-small cell lung cancer … in 50 patients with bronchoalveolar carcinoma has shown a …